Open Label Phase II Trial of Cabozantinib in Patients withMetastatic Castrate Resistant Prostate Cancer (mCRPC) andKnown Amplifications or Activating Mutations in Gene Targets of Cabozantinib who have Received Prior Anti Androgen Therapy

The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of prostate cancer. Cabozantinib (Cometriq™, Cabometyx™) is an oral medication that blocks activity of specific proteins in the body. It is approved by the Food and Drug Administration (FDA) for use in patients with medullary thyroid carcinoma and advanced renal cell carcinoma but is not approved to treat prostate cancer.

Are you Eligible? (Inclusion Criteria)

• Age >18 years.
• Evidence of metastatic Prostate Cancer on imaging (bone scan and/or CT/MRI scan) • Previously received either abiraterone acetate and/or enzalutamide or similar androgen receptor (AR) pathway inhibitor